Pfizer has announced the launch of a groundbreaking therapy for individuals living with hemophilia in the UAE. This new treatment represents a significant advancement in care for those affected by this serious and rare bleeding disorder.

Hemophilia is a genetic condition that impairs the blood’s ability to clot, resulting in prolonged bleeding that can occur spontaneously or after injury. Unlike conventional clotting factor replacements, Pfizer’s innovative therapy targets the tissue factor pathway inhibitor (TFPI), a natural anticoagulant protein. By inhibiting TFPI, this treatment aims to restore balance to the body’s clotting process, thereby reducing the frequency of bleeding episodes.

Administered once a week via a simple injection under the skin with a prefilled autoinjector pen, this therapy is the first of its kind available in the UAE. It is designed to enhance convenience and accessibility for patients while alleviating the challenges associated with frequent infusions.

Dr. Nadine Tarcha, Pfizer Gulf Medical Director, emphasized that the launch of this therapy underscores Pfizer’s commitment to improving the lives of people with rare diseases. She stated that by merging scientific innovation with a more convenient delivery method, the goal is to empower individuals with hemophilia to live with greater confidence and improved quality of life.

According to the World Federation of Hemophilia’s 2023 Annual Global Survey, over 32 000 individuals in the Eastern Mediterranean region have been diagnosed with hemophilia. This number is less than half of the anticipated cases, indicating that many may remain undiagnosed or lack access to appropriate care. These statistics highlight the critical need for early diagnosis and patient-friendly treatment options to support better long-term outcomes.

The introduction of this therapy aligns with the UAE’s broader healthcare vision, which emphasizes access to innovative treatments and enhanced quality of care for individuals with complex and rare conditions. Patients are advised to consult with their healthcare providers to explore whether this new treatment option is appropriate for their condition.

Pfizer is dedicated to applying science and resources to deliver therapies that significantly improve and extend patients’ lives. The company aims to set the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products, including innovative medicines and vaccines. Pfizer employees work globally to advance wellness, prevention, treatments, and cures for some of the most challenging diseases, collaborating with healthcare providers, governments, and communities to enhance access to affordable healthcare worldwide.